E. Erdman, K. Werdan, L. Brown (1985). Multiplicity of cardiac glycoside receptors in the heart.
Trends Pharmacol. Sci. 6: 293–295.
T. Godfraind, A. de Pover, G. Castaneda Hernandez, M. Fagoo (1982). Cardiodigin: endogenous
digitalis-like material from mammalian heart. Arch. Int. Pharmacodyn. 258: 165–167.
P. Lindberg, P. Norberg, T. Alminger, A. Brändsträm, B. Wallmark (1986). The mecha-
nism of action of the gastric acid secretion inhibitor omeprazole. J. Med. Chem. 29:
1327–1329.
H. Lullmann, T. Peters, A. Ziegler (1979). Kinetic events determining the effect of cardiac
glycosides.Trends Pharmacol. Sci. 1: 102–106.
K. Repke (1985). New developments in cardiac glycoside structure–activity relationships. Trends
Pharmacol. Sci. 6: 275–278.
D. C. Rohrer, D. S. Fullerton, K. Yoshioka, A. H. L. Frome, K. Ahmed (1979). Functional
receptor mapping for modified cardenolides: use of the Prophet system. In: E. C. Olson,
R. E. Christoffersen (Eds.). Computer Assisted Drug Design. Washington, DC: American
Chemical Society, pp. 259–279.
R. Thomas, J. Boutagy, A. Gelbart (1974). Synthesis and biological activity of semisynthetic
digitalis analogs. J. Pharmacol. Sci. 63: 1649–1683.
B. Wetzel, N. Hanel (1984). Cardiotonic agents. Annu. Rep. Med. Chem. 19: 71–80.
Enzyme Targets: Carbonic Anhydrase
E. J. Cragoe, Jr (Ed.) (1983). Diuretics: Chemistry, Pharmacology and Medicine. New York:
Wiley.
S. P. Gupta (2003). Quantitative structure–activity relationships of carbonic anhydrase inhibitors.
Prog. Drug Res. 60: 171–204.
H. R. Jacobsen, J. K. Kokko (1976). Diuretics: sites and mechanism of action. Annu. Rev.
Pharmacol. Toxicol. 16: 201–226.
K. K. Kannan, I. Vaara, B. Notstrand, S. Lovgren Borell, K. Fridborg, M. Petef (1977). Structure
and function of carbonic anhydrase: comparative studies of sulfonamide binding to human
erythrocyte carbonic anhydrases B and C. In: G. C. K. Roberts (Ed.). Drug Action at the
Molecular Level. Baltimore: University Park Press, pp. 73–91.
R. L. Smith, O. W. Woltersdorf, Jr, E. J. Cragoe, Jr (1976, 1978). Diuretics. Annu. Rep. Med.
Chem. 11: 71–79; 13 : 61–70.
C. T. Supuran, D. Vullo, G. Manole, A. Casini, A. Scozzafava (2004). Designing of novel
carbonic anhydrase inhibitors and activators. Curr. Med. Chem. Cardiovasc. Hematol.
Agents 2: 49–68.
Enzyme Targets: Monoamine Oxidase
F. P. Bymaster, R. K. McNamara, P. V. Tran (2003). New approaches to developing antidepres-
sants by enhancing monoaminergic neurotransmission. Expert Opin. Invest. Drugs 12:
531–543.
J. van Dijk, J. Hartog, F. C. Hillen (1978). Non-tricyclic antidepressants. In: G. P. Ellis,
G. B. West (Eds.). Progress in Medicinal Chemistry,vol. 15. Amsterdam: Elsevier/North
Holland, pp. 261–320.
J. Knoll (1982). Selective inhibition of B-type monoamine oxidase in brain: a drug strategy to
improve quality of life in senescence. In: J.A. Keverling Buisman (Ed.). Strategy in Drug
Research. Amsterdam: Elsevier.
ENDOGENOUS MACROMOLECULES 539